|
8:00 AM
|
Opening Remarks
Charis Eng MD, PhD
Kristin Anthony, President, PTEN Hamartoma Tumor Syndrome Foundation
Claudio Ales, President, PTEN Italia
|
|
8:15 AM
|
PTEN Hamartoma Tumor Syndrome 101*
Charis Eng, MD, PhD
|
|
8:45 AM
|
Patient Experience Panel*
Moderator: Robyn Busch, PhD
|
|
9:15 AM
|
Stress and Resilience in Coping with PHTS*
Karen Hurley, PhD
|
|
9:45 AM
|
Break
|
|
10:00 AM
|
Morning Keynote: PTEN Biology and Therapeutics
Pier Paolo Pandolfi, MD, PhD, FRCP
|
|
10:25 AM
|
Hereditary Breast Cancer and Hormone Use
Holly Pederson, MD, NCMP
|
|
10:50 AM
|
Gynecologic Cancer Risks in PTEN Hamartoma Tumor Syndrome
Chad Michener, MD
|
|
11:15 AM
|
PTEN & Cancer Panel*
Moderator:
Takae Brewer, MD
Panelists:
Charis Eng, MD, PhD
Chad Michener, MD
Pier Paolo Pandolfi, MD, PhD, FRCP
Holly Pederson, MD, NCMP
|
|
11:40 AM
|
Lunch/PTEN Patient and Family Virtual Meet Up (optional, non- CME)
|
|
12:40 PM
|
Afternoon Keynote: PTEN and Neurodevelopment
Thomas W. Frazier, PhD
|
|
1:05 PM
|
PTEN Hamartoma Tumor Syndrome in Childhood (with focus on NDD)
Katherine Lachlan, MBChB, FRCP
|
|
1:30 PM
|
Natural History Study of NDD Phenotypes in PHTS
Robyn Busch, PhD
|
|
1:55 PM
|
Models to Study Neurodevelopmental Aspects of PTEN Hamartoma Tumor Syndrome
Mustafa Sahin, MD, PhD
|
|
2:20 PM
|
Defining Neurological Phenotypes to Establish Clinical Guidelines in PTEN Hamartoma Tumor Syndrome*
Andrew Dhawan, MD, DPhil
|
|
2:35 PM
|
PTEN & Neurodevelopment Panel*
Moderator:
Andrew Dhawan, MD, DPhil
Panelists:
Robyn Busch, PhD
Thomas W. Frazier, PhD
Katherine Lachlan, MBChB, FRCP
Mustafa Sahin, MD, PhD
|
|
3:00 PM
|
Break
|
|
3:15 PM
|
A Randomized Double-Blind Controlled Trial of Everolimus in Individuals with PTEN Mutations*
Antonio Hardan, MD
|
|
3:45 PM
|
PTEN-related Vascular Anomalies and Management*
Denise Adams, MD
|
|
4:15 PM
|
Refined Surveillance Recommendations for Thyroid Disease in PTEN Hamartoma Tumor Syndrome*
Gilman Plitt, MD
|
|
4:30 PM
|
The Genomic Landscape of Breast Cancers in PTEN Hamartoma Tumor Syndrome*
Takae Brewer, MD
|
|
4:45 PM
|
Closing Remarks
Charis Eng MD, PhD
Kristin Anthony
Claudio Ales
|
|
5:00 PM
|
Adjourn
|
|
|
*A 5-10 minute Q&A is included in each speaker’s allotted time.
|
